Clinical Trial Update: Study Evaluating Aerosol and Intradermal Administration of a Candidate Tuberculosis (TB) Vaccine, MVA85A, as a Way to Increase Immune Response and Avoid Anti-vector Immunity [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating aerosol and intradermal delivery of the TB vaccine MVA85A to enhance immune response and reduce anti-vector immunity; the study has com…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tuberculosis

Drugs mentioned

• MVA85A (Modified Vaccinia Ankara expressing antigen 85A)

Snippet

Sponsor: University of Oxford | Conditions: Tuberculosis | Phase 1 | Status: COMPLETED